Cover Image

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation

Refinement of immunosuppressive strategies has led to further improvement of kidney graft survival in recent years. Currently, the main limitations to long-term graft survival are life-threatening side effects of immunosuppression and chronic allograft injury, emphasizing the need for innovative imm...

Full description

Saved in:
Bibliographic Details
Main Authors: Morath, Christian (Author) , Schmitt, Anita (Author) , Kälble, Florian (Author) , Zeier, Martin (Author) , Schmitt, Michael (Author) , Şandra-Petrescu, Flavius Ionuţ (Author) , Opelz, Gerhard (Author) , Terness, Peter (Author) , Schaier, Matthias (Author) , Kleist, Christian (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: Pediatric nephrology
Year: 2017, Volume: 33, Issue: 2, Pages: 199-213
ISSN:1432-198X
DOI:10.1007/s00467-017-3599-2
Online Access:Verlag, Pay-per-use, Volltext: http://dx.doi.org/10.1007/s00467-017-3599-2
Verlag, Pay-per-use, Volltext: https://link.springer.com/article/10.1007/s00467-017-3599-2
Get full text
Author Notes:Christian Morath, Anita Schmitt, Florian Kälble, Martin Zeier, Michael Schmitt, Flavius Sandra-Petrescu, Gerhard Opelz, Peter Terness, Matthias Schaier, Christian Kleist
Description
Summary:Refinement of immunosuppressive strategies has led to further improvement of kidney graft survival in recent years. Currently, the main limitations to long-term graft survival are life-threatening side effects of immunosuppression and chronic allograft injury, emphasizing the need for innovative immunosuppressive regimens that resolve this therapeutic dilemma. Several cell therapeutic approaches to immunosuppression and donor-specific unresponsiveness have been tested in early phase I and phase II clinical trials in kidney transplantation. The aim of this overview is to summarize current cell therapeutic approaches to immunosuppression in clinical kidney transplantation with a focus on myeloid suppressor cell therapy by mitomycin C-induced cells (MICs). MICs show great promise as a therapeutic agent to achieve the rapid and durable establishment of donor-unresponsiveness in living-donor kidney transplantation. Cell-based therapeutic approaches may eventually revolutionize immunosuppression in kidney transplantation in the near future.
Item Description:Published online: 23 February 2017
Gesehen am 07.05.2018
Physical Description:Online Resource
ISSN:1432-198X
DOI:10.1007/s00467-017-3599-2

Similar Items